Humanized firefly luciferase (Luc2)
Codon-optimized firefly luciferase engineered for enhanced expression in mammalian cells with improved thermostability and reduced cryptic regulatory elements. Synthetic optimization of Photinus pyralis luciferase achieves 3-10× higher signal intensity than wild-type in reporter assays with same ATP-dependent catalytic mechanism.
Origin: Codon optimization from Photinus pyralis luciferase
Characteristics
Synthetic gene design removes cryptic transcription factor binding sites, TATA boxes, and chi sites present in wild-type firefly luciferase sequence while maintaining identical amino acid sequence (551 aa, 61 kDa). Optimized codon usage for mammalian translation machinery produces higher steady-state protein levels. Enhanced thermostability at 37°C compared to wild-type enzyme with reduced signal decay over extended assay periods. Exhibits same ATP-dependent catalytic mechanism with D-luciferin producing yellow-green bioluminescence with temperature-dependent 34 nm spectral shift. Signal intensity 3-10× higher than unoptimized luciferase in transfected mammalian cells. Forms basis of pGL4 reporter vector series with improved response dynamics and reduced background.
Applications: High-sensitivity transcriptional reporter assays in mammalian cell culture with enhanced signal-to-noise ratio. Dual-luciferase assays paired with Renilla luciferase for normalized measurements of promoter activity. High-throughput screening of drug candidates, pathway activation, and gene regulation. In vivo bioluminescence imaging of tumor xenografts and therapeutic response in mouse models. ATP quantification and cell viability assays with improved detection sensitivity down to sub-picogram levels. Protein-protein interaction studies and real-time monitoring of cellular processes.
Limitations: Yellow-green emission at 560 nm (25°C) experiences moderate tissue attenuation in deep tissue imaging similar to wild-type firefly luciferase, though 37°C spectral shift to 612 nm improves penetration. Requires D-luciferin substrate injection for in vivo applications with blood-brain barrier permeability. Flash-type kinetics necessitates continuous substrate availability or rapid measurement protocols. Codon optimization specific to mammalian systems may not provide expression benefits in bacterial, yeast, or plant hosts. Product inhibition by oxyluciferin accumulation at high substrate concentrations.